Compass Therapeutics, Inc. · NASDAQ:CMPX
Compass Therapeutics — Investor Presentation (September 2026)
45 slides from Compass Therapeutics's investor presentation, September 2026
Slide 1: Bringing Transformative Oncology Therapies to Patients
Bringing Transformative Oncology Therapies to Patients Corporate Presentation I September 2026 Nasdaq: CMPX1
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Compass Therapeutics, Inc. ("we," "us," "our," or the “Company”). Statements contained herein are made as of the date of this presentation unless stated otherwise, and this presentation shall not under any circumstances create an implication that the
Slide 3: A Leader in Next-Generation Oncology Therapies
A Leader in Next-Generation Oncology Therapies Tovecimig: Innovative Solid Foundation Lead Near-Commercial Asset Oncology Pipeline For Growth Bispecific antibody targeting DLL4 x Novel and diverse pipeline including $180M cash and marketable securities VEGF-A potential first- and best-in-class drugs
Slide 4: Diversified & Robust Pipeline with Multiple Value Inflection Points
Diversified & Robust Pipeline with Multiple Value Inflection Points Program Target Preclinical Phase 1 Phase 2 Phase 3 Next Steps Biliary Tract Cancer (2L) Planning BLA submission Tovecimig DLL4 x VEGF-A Planning Phase 2 based on BTC efficacy data Solid Tumors (+/- paclitaxel) (potential: gastric, o
Slide 5: Tovecimig (CTX-009)
Tovecimig (CTX-009) DLL4 X VEGF-A bispecific antibody Nasdaq: CMPX5
Slide 6: Tovecimig: Dual Targeting of DLL4 and VEGF to Maximize Anti-Angiogenesis
Tovecimig: Dual Targeting of DLL4 and VEGF to Maximize Anti-Angiogenesis Anti-VEGF-A disrupts tumor vessel formation (a validated anti-angiogenic mechanism) while anti-DLL4 targets DLL4-Notch 1 signaling and alters perfusion in tumor vessels that are resistant to anti-VEGF therapies. 1. PMID: 174573
Slide 7: Strong Monotherapy Activity in Multiple Refractory Tumor Types
Strong Monotherapy Activity in Multiple Refractory Tumor Types 100 90 CRC 80 0.3 70 Gastric 60 Other Tumor Growth (%) 0.3 50 12.5 12.5 40 0.3 30 Phase 1a – Dose Escalation1 20 2.5 12.5 17.5 12.5 5.0 7.5 7.5 5.0 10 10.0 15.0 2.5 15.0 12.5 1.0 12.5 12.5 1.0 17.5 12.5 0 n=40 evaluable -10 15.0 5.0 10.0
Slide 8: Strong Combination Activity in Multiple Refractory Tumor Types
Strong Combination Activity in Multiple Refractory Tumor Types Solid Tumors Tovecimig + paclitaxel OR Tovecimig + irinotecan 50 40 30 Tumor Growth (%) 20 10 RECIST v1.1 Partial Responses Phase 1b – Combination1 0 paclitaxel -10 -20 n=17 evaluable -30 dosed at 10 or 12.5 mg/kg -40 Gastric Pancreatic
Slide 9: Pivotal Phase 2/3 COMPANION-002 Trial in BTC Study Design
Pivotal Phase 2/3 COMPANION-002 Trial in BTC Study Design Study Treatment – 28 Day Cycles Tovecimig + Paclitaxel n=111 168 patients across 34 sites in the U.S. Disease Follow-up approx. progression per Inclusion Criteria Tovecimig 10mg/kg every 3 months RECIST v1.1* • Progression after a prior gemci
Slide 10: COMPANION-002: Well-Balanced Baseline Demographics
COMPANION-002: Well-Balanced Baseline Demographics Tovecimig + Paclitaxel Paclitaxel (n=111) (n=57) Age Median (years) 65.0 63.0 Male 53 (47.7) 24 (42.1) Sex Female 58 (52.3) 33 (57.9) Asian 17 (15.3) 10 (17.5) White 84 (75.7) 40 (70.2) Race African American 4 (3.6) 6 (10.5) Unknown/Other 6 (5.4) 1
Slide 11: COMPANION-002: Significant Improvement in Primary Endpoint of ORR
COMPANION-002: Significant Improvement in Primary Endpoint of ORR Tovecimig Paclitaxel + Paclitaxel Intent-to-Treat Population n=111 n=57 Overall Response Rate (CR+PR) 20 (18.0%) 3 (5.3%) Two-Sided p-value p=0.0228 Complete Response (CR) 1 (0.9%) 0 (0.0%) Best Partial Response (PR) 19 (17.1%) 3 (5.3
Slide 12: COMPANION-002: Tovecimig Significantly Improved PFS (BICR-Assessed)
COMPANION-002: Tovecimig Significantly Improved PFS (BICR- Assessed) ITT Analysis: HR=0.44, p<0.0001, 4.7 vs. 2.6 months median PFS Censored Tovecimig + paclitaxel Paclitaxel alone Tovecimig + paclitaxel Paclitaxel alone Data cutoff from COMPANION-002 as of June 2026. 12
Slide 13: COMPANION-002: OS Analysis Confounded by Crossover
COMPANION-002: OS Analysis Confounded by Crossover ITT analysis: HR=1.05, p=0.78, 8.9 vs. 9.4 months median OS Control arm includes: 31 patients (54%) who crossed over and received tovecimig plus paclitaxel (with a median OS of 12.8 months) 26 patients (46%) who received paclitaxel alone (with a med
Slide 14: COMPANION-002: Tovecimig Improved PFS2 Post-Crossover
COMPANION-002: Tovecimig Improved PFS2 Post-Crossover Prespecified secondary analysis (n=31): HR=0.54, p=0.065, 3.5 vs. 1.9 months median PFS Data cutoff from COMPANION-002 as of June 2026. 14
Slide 15: COMPANION-002: Tovecimig Significantly Improved OS in Crossover Patients
COMPANION-002: Tovecimig Significantly Improved OS in Crossover Patients Post hoc subset analysis (n=31 vs. n=26): HR=0.54, p=0.04, 12.8 vs. 6.1 months median OS Data cutoff from COMPANION-002 as of June 2026. 15
Slide 16: COMPANION-002: Crossover Patients Progressed Faster on Paclitaxel Monotherapy
COMPANION-002: Crossover Patients Progressed Faster on Paclitaxel Monotherapy than Patients Who Did Not Crossover Post hoc subset analysis (n=31 vs. n=26): 1.9 vs. 3.6 months median PFS, p=0.007 Data cutoff from COMPANION-002 as of June 2026. 16
Slide 17: COMPANION-002 Safety: Treatment Emergent Adverse Events
COMPANION-002 Safety: Treatment Emergent Adverse Events ≥ 20% (Combination Arm) Safety profile generally consistent with previously reported data Tovecimig + Paclitaxel Paclitaxel n=108 n=53 Related Related n (%) Overall Related ≥ Grade 3 Overall Related ≥ Grade 3 ≥ Grade 3 ≥ Grade 3 Fatigue 72 (67)
Slide 18: COMPANION-002: Study Summary and Next Steps
COMPANION-002: Study Summary and Next Steps Endpoint / Results Analysis ORR Primary Significant improvement: 18.0% vs 5.3% BICR-assessed ORR (p=0.0228) PFS Key Secondary Significant improvement: 4.7 vs 2.6 months median PFS (HR=0.44, p<0.0001) OS confounded by crossover: 8.9 vs 9.4 months median OS
Slide 19: Tovecimig: Potential to Become Standard of Care in 2L BTC
Tovecimig: Potential to Become Standard of Care in 2L BTC Months Analysis Program N ORR 0 2 4 6 8 10 12 14 Tovecimig COMPANION-002 Study in 2L* 111 18% 4.7 m 8.9 m Combo (p=0.0228) Tovecimig + ITT Paclitaxel 57 2.6 m 9.4 m 5.3% OS analysis includes crossover patients Control 31 1.9 m 3.5m 5.4m (
Slide 20: Tovecimig (CTX-009) Commercial Opportunity
Tovecimig (CTX-009) Commercial Opportunity Nasdaq: CMPX 20
Slide 21: Significant Unmet Need in Biliary Tract Cancer Treatment Remains Despite Recent Advances
Significant Unmet Need in Biliary Tract Cancer Treatment Remains Despite Recent Advances Right lobe of liver Left lobe of liver High unmet need exists for effective options for patients with BTC Many patients present at late stage, leading to poor prognosis of ~10-15% 5-year survival1 Intrahepatic b
Slide 22: Treatment Landscape Allows for a Targeted Launch in a Potential TAM of Over $3 Billion
Treatment Landscape Allows for a Targeted Launch in a Potential Total Addressable Market (TAM) of Over $3 Billion Concentrated treatment landscape of BTC Over 15K patients/yr potentially eligible for tovecimig >26,5001,2 patients diagnosed with BTC (growing to ~34K by 2037) ~250 High Volume BTC Acco
Slide 23: Significant Expansion Opportunity for Tovecimig Beyond 2L BTC
Significant Expansion Opportunity for Tovecimig Beyond 2L BTC Annual U.S. Incidence of DLL4-Enriched Solid Tumors1-5 Tovecimig clinical activity demonstrated Avastin approved indication6 Paclitaxel approved indication7,8,9 154K 354K 73K 35K 30K 27K 20K 15K Glioblastoma Ovarian BTC GC HCC RCC CRC Tot
Slide 24: Tovecimig – Advancing to Approval in BTC and Beyond
Tovecimig – Advancing to Approval in BTC and Beyond Strong Clinical Data in a Difficult Indication Robust evidence of activity in patients with BTC Generally well tolerated, with no new safety signal No approved therapeutics for most patients in 2L setting Near-Term Regulatory Milestones Expected Pl
Slide 25: CTX-8371
CTX-8371 PD-1 x PD-L1 bispecific antibody Nasdaq: CMPX 25
Slide 26: PD-1 and PD-L1 are Validated Targets That Have Transformed Oncology, Yet Unmet Needs Remain
PD-1 and PD-L1 are Validated Targets That Have Transformed Oncology, Yet Unmet Needs Remain ~57% of advanced cancer patients are eligible for checkpoint therapy1 CPIs transformed oncology Checkpoint inhibitors (CPIs) are approved in 20+ tumor types and 80+ lines / indications2,3 ~80% of CPI-treated
Slide 27: CTX-8371: Identified Using StitchMabs Platform
CTX-8371: Identified Using StitchMabs Platform Engineered Synergistic Activity Proprietary Superior of PD-1 / PD-L1 in StitchMabs format Structural Design Activity T-cell activation assay vs + PD-1xPD-L1 v1 PD-1xPD-L1 v2 Keytruda PD-1 Nivolumab Isotype Control No Ab Control MC38-hPD-L1 model implant
Slide 28: Novel Mechanism of Action Leads to Amplified Anti-Tumor T Cell Activity
Novel Mechanism of Action Leads to Amplified Anti-Tumor T Cell Activity PMID: 38379869 28
Slide 29: CTX-8371: Ongoing Phase 1 Study
CTX-8371: Ongoing Phase 1 Study Inclusion Criteria Part A: Dose Escalation Part B: Dose Expansion 10.0 mg/kg n=3-6 Group 1 (3.0 mg/kg): 3.0mg/kg A1: NSCLC, n=14 n=3-6 B1: TNBC, n=14 Post-PD-1 or PD-L1 C1: HL n= 6 patients with NSCLC, TNBC, 1.0mg/kg Dose Patients followed HL, HNSCC, n=3-6 Determinati
Slide 30: CTX-8371 in TNBC: Confirmed, Deep and Durable Partial Response
CTX-8371 in TNBC: Confirmed, Deep and Durable Partial Response Baseline Week 8 Week 48 Triple-Negative Right Lobe Breast Cancer Nodule >90% reduction 20 mm 0 mm 0 mm in target tumor lesions in one patient (4th line) 87 mm total target lesions Pericardial at baseline Mass (3 target lesions) 52 mm 0 m
Slide 31: CTX-8371 in HL: Metabolic Partial Response
CTX-8371 in HL: Metabolic Partial Response Reduction of Deauville Score from 5 at Baseline to 3 at Week 24 Baseline Week 24 AC Node Periportal Node Peripancreatic Node Previously treated with: ABVD (1L) BEAM/stem cell transplant (2L) nivolumab/brentuximab (3L) 31
Slide 32: CTX-8371 in NSCLC: Complete Resolution of Target Lesions
CTX-8371 in NSCLC: Complete Resolution of Target Lesions Baseline Week 8 Week 16 45 mm 18 mm 0 mm Non-Small Cell Lung Cancer Complete resolution of target tumor lesions in one patient after initial pseudo-progression 4th line with 59 mm total target lesion burden @ baseline Previously treated with:
Slide 33: CTX-10726
CTX-10726 PD-1 x VEGF-A bispecific antibody Nasdaq: CMPX 33
Slide 34: CTX-10726: Potential Best-in-Class PD-1 x VEGF-A Bispecific
CTX-10726: Potential Best-in-Class PD-1 x VEGF-A Bispecific Transgenic Mouse Model (MC38) Human NSCLC (HCC827) Xenografts1 (express human PD-1/PD-L1) Treated with human PBMCs and indicated antibodies CTX-10726 Testing both PD-1 and VEGF-A targeting 1000 Average Tumor Volume Anti-VEGF: Clinically pro
Slide 35: Phase 1 of CTX-10726 Study Design
Phase 1 of CTX-10726 Study Design Inclusion Criteria Cohort 1 Cohort 2 CTX-10726 Single Agent CTX-10726 Single Agent Dose Escalation Dose Expansion 10mg/kg n=3-6 Dose Level(s) and Tumor SMC Recommends Types TBD Post-PD-1 or PD-L1 3.0mg/kg Expansion n=40 patients with n=3-6 RCC, HCC, gastric cancer o
Slide 36: CTX-471
CTX-471 CD137 agonist Nasdaq: CMPX 36
Slide 37: Response to CTX-471 was Associated with High NCAM Expression in the Phase 1 Study
Response to CTX-471 was Associated with High NCAM Expression in the Phase 1 Study CTX-471 is a potential best-in-class CD137 (4-IBB) Monotherapy Phase 1b post-PD-1 in 60 agonist targeting a unique epitope with an patients with 17 different tumor types: optimized affinity Compelling anti-tumor activi
Slide 38: CTX-471: Complete Response in a Patient with Small Cell Lung Cancer
CTX-471: Complete Response in a Patient with Small Cell Lung Cancer Baseline Month 4 Month 32 Small Cell Lung CTX-471 treated patient with advanced SCLC had a PET negative complete response after ~3 years on therapy Previously treated with: carboplatin/etoposide plus atezolizumab (1L), and nivolumab
Slide 39: CTX-471: Novel Mechanism of Action for NCAM (CD56)+ Tumors
CTX-471: Novel Mechanism of Action for NCAM (CD56)+ Tumors 39
Slide 40: Phase 2 Study Design of CTX-471 in Patients with NCAM+ Tumors
Phase 2 Study Design of CTX-471 in Patients with NCAM+ Tumors Stage 1 Stage 2 Eligibility Criteria: • Patients with locally advanced or metastatic Grade 3 neuroendocrine 0.3 mg/ kg yes 0.3 mg/ kg tumors (NET) or neuroendocrine ORR ≥ 3/18 carcinomas (NEC) n=18 evaluable patients n=11 evaluable patien
Slide 41: NCAM Positive Tumors Represent a Significant Opportunity for CTX-471
NCAM Positive Tumors Represent a Significant Opportunity for CTX-471 US 2023 – SEER Database1 37,000 67,300 14,700 5,600 3,200 2,900 2,400 1,500 Colon NET NSCLC NET Prostate NET Pancreatic NET Metastatic/ Glioblastoma* SCLC* Total Melanoma * ~100% NCAM+ 1. Seer database 41
Slide 42: Milestones
Milestones Nasdaq: CMPX 42
Slide 43: Key Anticipated Milestones
Key Anticipated Milestones 2025 1H 2026 2H 2026 April 2026 2H 2026 Ph 2/3 Data (2L) Q3 2026 Ph 2/3 Data (2L) Planning BLA ORR FDA Meeting Tovecimig BTC PFS / OS submission (DLL4 x VEGF-A) Initiated Ph 2 IST (1L) Tovecimig Planning for next studies (DLL4 x VEGF-A) CTX-471 Q3 2026 (CD137) Initiate Ph
Slide 44: Leadership Team Experienced in Drug Discovery, Development, and Commercialization
Leadership Team Experienced in Drug Discovery, Development, and Commercialization Thomas J. Schuetz, MD, PhD Barry Shin, JD, MBA Cynthia Sirard, MD President, CEO, & Chief Financial Officer Chief Medical Officer Vice Chairman of the Board Arjun Prasad, MBA, MPH Bing Gong, PhD Jon Anderman, JD Neil L
Slide 45: Compass Therapeutics
Compass Therapeutics Website: compasstherapeutics.com Nasdaq: CMPX 45 Nasdaq: CMPX
Compass Therapeutics — Investor Presentation (September 2026) on 6ix